[Form 4] aTYR PHARMA INC Insider Trading Activity

Rhea-AI Filing Summary

aTYR Pharma (ATYR) director Paul Schimmel reported purchases totaling 1,000,000 common shares across 10/08/2025 and 10/09/2025 at weighted average prices of $0.898 and $0.9414 respectively. After these transactions the reporting person beneficially owned 1,413,023 shares indirectly through trusts and a prototype PSP vehicle. The filings note share purchase price ranges from $0.8536 to $0.95 for the first lot and $0.93 to $0.95 for the second, and identify ownership via the Paul Schimmel Prototype PSP and the Schimmel Revocable Trust.

Positive

• Director purchased 1,000,000 shares in open-market transactions on 10/08/2025 and 10/09/2025
• Beneficial ownership increased to 1,413,023 shares, signaling greater insider stake
• Shares acquired at sub-$1 weighted average prices ($0.898 and $0.9414), indicating material insider buying at low prices

Negative

• None.

Insights

Corporate Insider Trading Analyst

Director purchased 1.0M shares at sub-$1 prices, increasing indirect stake to 1,413,023 shares.

Insider purchases by a director at reported prices between $0.8536 and $0.95 increased beneficial ownership to 1,413,023 shares, held indirectly via trust and a prototype PSP vehicle. The filings provide weighted average prices and ranges for the two purchase dates of 10/08/2025 and 10/09/2025.

Key dependencies are the exact share counts per price (available on request per the filing) and that ownership remains indirect through trust structures. Watch any future Form 4s for changes in direct vs indirect holdings or additional open-market buys within the next quarter.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHIMMEL PAUL

(Last) (First) (Middle)

C/O ATYR PHARMA, INC.

10240 SORRENTO VALLEY ROAD, SUITE 300

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
aTYR PHARMA INC [ ATYR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/08/2025		P		682,001	A	$0.898(1)	1,095,024	I	See Footnote(2)
Common Stock	10/09/2025		P		317,999	A	$0.9414(3)	1,413,023	I	See Footnote(2)
Common Stock								8,890	D
Common Stock								679,143	I	See Footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents weighted average price for the shares. The shares were purchased at prices ranging from $0.8536 to $0.95 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.

2. These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel.

3. Represents weighted average price for the shares. The shares were purchased at prices ranging from $0.93 to $0.95 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.

4. These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000.

	/s/ Nancy E. Denyes, as Attorney-in-Fact	10/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the ATYR Form 4 filed by Paul Schimmel disclose?

The Form 4 disclosed purchases of 682,001 shares on 10/08/2025 and 317,999 shares on 10/09/2025, raising beneficial ownership to 1,413,023 shares.

At what prices were the ATYR shares purchased by the director?

Weighted average prices were $0.898 for the 10/08/2025 purchases and $0.9414 for the 10/09/2025 purchases; individual trades ranged from $0.8536 to $0.95.

How is Paul Schimmel's ATYR ownership held according to the filing?

Ownership is indirect via Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel, and Schimmel Revocable Trust U/A Dtd 9/6/2000.

Do the filings show any dispositions by the reporting person?

The Form 4 shows a disposition of 8,890 shares listed concurrently, with the net effect increasing indirect beneficial ownership to 1,413,023 shares.

Where can I find details of how many shares were bought at each price?

The filing states that the reporting person will provide full information about the number of shares purchased at each separate price upon request to the SEC, the issuer, or any security holder.